Numab Therapeutics

Executive Summary

Numab Therapeutics is a Swiss biotechnology company pioneering multi-specific antibody therapeutics through its proprietary MATCH™ platform, which enables the design of stable, manufacturable antibodies that simultaneously engage multiple disease targets. Founded in 2011 and headquartered in Pfäffikon, Switzerland, Numab has raised approximately $50 million to advance its pipeline in oncology and immunology. The company's lead programs are in Phase 2 development, focusing on difficult-to-treat diseases where multi-specific antibodies may offer superior efficacy and safety over traditional monoclonal antibodies. Numab's platform technology is a key differentiator, potentially enabling faster development of complex biologics with improved drug-like properties. As a private Phase 2-stage company, Numab's near-term value is driven by clinical data readouts and platform validation. The company is well-positioned to benefit from growing interest in multi-specific therapeutics, with several industry partnerships and internal programs advancing. Key upcoming catalysts include Phase 2 data from its lead oncology candidate, which could validate the platform and attract licensing or collaboration interest. Additionally, Numab may pursue IND-enabling studies for new pipeline candidates or announce strategic partnerships to expand its pipeline. With a strong scientific foundation and a focus on high-unmet-need areas, Numab represents an attractive opportunity in the multi-specific antibody space.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 clinical data readout for lead oncology candidate60% success
• H1 2026IND submission for a new pipeline candidate in immunology50% success
• 2026Strategic partnership or licensing deal for platform technology70% success